Evidence for a critical role of catecholamines for cardiomyocyte lineage commitment in murine embryonic stem cells
3rd International Conference and Exhibition on Cell & Gene Therapy
October 27-29, 2014 Embassy Suites Las Vegas, USA

Martin Lehmann

Scientific Tracks Abstracts: J Stem Cell Res Ther

Abstract:

Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the blastocyst. These cells possess the ability of infinite self-renewal and to differentiate into all cell types of the three germ-layers. In defined conditions ES cells are committed to the mesodermal lineage and differentiate, amongst other cell types, into cardiomyocytes (CMs). The processes underlying mesodermal and subsequent cardiac differentiation are yet only partially understood. Catecholamine release is well known to modulate heart rate and force in adult mammals. Despite first evidence, only little is known about an involvement of catecholamines during embryonic heart development. Therefore our work aimed to investigate in more detail whether catecholamines are involved in the process of ES cell cardiac differentiation in vitro. Effects of catecholamine depletion induced by reserpine were investigated during murine D3 aPIG44 ES cell differentiation. Reserpine is a drug blocking vesicular storage of monoamines, and as a result depletes cells of the catecholamines norepinephrine and epinephrine. Cardiac differentiation was assessed by quantification of beating clusters, immunocytochemistry, molecular biology, flowcytometry and pharmacological approaches. Proliferation and cytotoxicity was evaluated by embryoid body cross-section measurements and impedance monitoring, while functional characterization of CMs was performed using extracellular field potential (FP) recordings with microelectrode arrays (MEAs). Involvement of b-adrenoceptor signaling was studied differentiating ES cells in the presence of reserpine and isoproterenol. To further discriminate between drug-specific effects of reserpine and catecholamine action via adrenergic receptors we applied the unspecific α- and β-receptor antagonists phentolamine and propranolol during differentiation. Reserpine treatment led to a remarkable reduction of beating cardiac clusters, downregulation of cardiac proteins α-actin and troponinT and delayed mesodermal and cardiac gene expression. In more detail, the average ratio of ~40% spontaneously beating control clusters was significantly reduced by 100%, 91.1% and 20.0% on days 10, 12, and 14, respectively. In line, significant reduction by 71.6% (n=11) of eGFP expressing CMs after reserpine treatment was revealed by flowcytometry. Reserpine neither reduced EB size nor acted cytotoxic on CMs, while increased numbers of neuronal cells were observed. MEA measurements with reserpine-treated EBs showed lower FP frequencies and weak responsiveness to adrenergic and muscarinic stimulation. Co-application of isoproterenol and reserpine during differentiation partially rescued cardiac development. The developmental inhibition after α- and β-adrenergic blocker application mimicked developmental changes with reserpine and proved an involvement of adrenergic receptors in the process. We therefore conclude that catecholamines and adrenergic signaling play a critical role during cardiac development in ES cells.

Biography :

Martin Lehmann has completed his PhD in 2014 from the University of Cologne. He currently works as a Postdoctoral Marie-Curie Fellow for the Institute of Neurophysiology of the University Hospital of the University of Cologne on a EU-granted project, performing parts of his research in a Biotechnology Company in Budapest (Hungary).